Expectations trend
FY2028 · fiscal year ending 2028-02-28 · fmp
LOOP INDUSTRIES INC (LOOP)
NASDAQMaterialsChemicals - SpecialtySnapshot 2026-11-04
$0.25-5.60%
Close 2026-11-05 · 1-day change
NASDAQMaterialsChemicals - SpecialtySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for LOOP yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Revenue grows toward $11.64 million by 2026-02-28 | A supporting condition in LOOP INDUSTRIES INC's published investment case. The stated target is >= 11.64 million USD. | Broken | revenue falls below $11 million in fiscal 2026 | Revenue: $117,000 FY2027-Q2; GAAP. Published target: >= 11.64 million USD. Target period ends 2026-02-28; this observation covers 2027-Q2. Oct 16, 2026117,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-02-28 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth thesis, not a proven durable compounder, because the company is loss-making and faces high risk. The multi-year view is in a watch state: management has made some cost reductions, but delivery on major facility plans remains mixed.
The valuation model shows LOOP at a premium to peers, while the expectations gap is substantial and the valuation signal is tagged unjustified. Fragility is rated low, but that does not remove the gap between expectations and the company's current results.
Near term, consecutive earnings misses and a 51% estimated miss probability make the next results a key watch point, despite the October report being in line. Over the multi-year thesis, lower operating costs are measurable progress, but India financing is unresolved and the supplied financial results show limited evidence of progress in Europe.
The thesis would improve if LOOP reverses its lowered guidance and raises it next quarter, while continued strength from Materials-sector bellwethers could support the sector backdrop. It would weaken if those bellwethers miss or guide lower, or if LOOP cannot secure financing and deliver its facility plans.
Over the next 1 to 3 years, LOOP's thesis rests on turning cost control and facility planning into sustained operating progress, while addressing near-term execution risk and a valuation that appears demanding versus peers. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Cash flow losses are improving, down to negative $2.7M. |
| Improving |
| operating cash flow loss worsens beyond -2.7 million USD after 2026-Q4 |
Cash from operations: $-1.165M FY2027-Q2; GAAP. Published target: >= -2.7 million USD operating cash flow. The stored target says 2026-Q4; this source reports FY2027-Q2. Fiscal/calendar alignment needs review. Oct 15, 2026-1,165,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Capital expenditure for India facility stays near $165-170 million | They lowered capital costs for their India plant to about $167.5M. | Intact | capital expenditure for India facility rises above $170 million | Capital expenditures: $47,000 FY2027-Q2; GAAP. Published target: 165 to 170 million USD. The stored target says 2026-Q4; this source reports FY2027-Q2. Fiscal/calendar alignment needs review. Oct 15, 202647,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Net loss improves to no worse than negative $2.7 million by 2026-Q4 | Cash flow losses are improving, down to negative $2.7M. | Broken | net loss worsens beyond -2.7 million USD in any quarter after 2026-Q4 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.03 → $-0.09 · observed estimates
$0.03B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-07-25 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-07-26 | $-0.25 | $1,074,500 | 1 / 1 |
| 2026-07-27 | $-0.25 | $1,074,500 | 1 / 1 |
| 2026-07-28 | $-0.25 | $1,074,500 | 1 / 1 |
| 2026-07-29 | $-0.25 | $1,074,500 | 1 / 1 |
| 2026-07-30 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-07-31 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-08-01 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-08-02 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-08-03 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-08-04 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-08-05 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-08-06 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-08-07 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-08-08 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-08-09 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-08-10 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-08-12 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-08-13 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-08-14 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-08-15 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-08-16 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-08-17 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-08-18 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-08-19 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-08-20 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-08-21 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-08-22 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-08-23 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-08-24 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-08-25 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-08-26 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-08-27 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-08-28 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-08-29 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-08-30 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-08-31 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-09-01 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-09-02 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-09-03 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-09-04 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-09-05 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-09-06 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-09-07 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-09-08 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-09-09 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-09-10 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-09-11 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-09-12 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-09-13 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-09-14 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-09-15 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-09-16 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-09-17 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-09-18 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-09-19 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-09-20 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-09-21 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-09-22 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-09-23 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-09-24 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-09-25 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-09-26 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-09-27 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-09-28 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-09-29 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-09-30 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-10-01 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-10-02 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-10-03 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-10-04 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-10-05 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-10-06 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-10-07 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-10-08 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-10-09 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-10-10 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-10-11 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-10-12 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-10-13 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-10-14 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-10-15 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-10-16 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-10-17 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-10-18 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-10-19 | $0.03 | $33,950,000 | 1 / 1 |
| 2026-10-20 | $-0.09 | $7,025,000 | 1 / 1 |
| 2026-10-21 | $-0.09 | $7,025,000 | 1 / 1 |
| 2026-10-22 | $-0.09 | $7,025,000 | 1 / 1 |
| 2026-10-23 | $-0.09 | $7,025,000 | 1 / 1 |
| 2026-10-24 | $-0.09 | $7,025,000 | 1 / 1 |
| 2026-10-25 | $-0.09 | $1,150,000 | 1 / 1 |
| 2026-10-26 | $-0.09 | $1,150,000 | 1 / 1 |
| 2026-10-27 | $-0.09 | $1,150,000 | 1 / 1 |
| 2026-10-28 | $-0.09 | $1,150,000 | 1 / 1 |
| 2026-10-29 | $-0.09 | $1,150,000 | 1 / 1 |
| 2026-10-30 | $-0.09 | $1,150,000 | 1 / 1 |
| 2026-10-31 | $-0.09 | $1,150,000 | 1 / 1 |
| 2026-11-01 | $-0.09 | $1,150,000 | 1 / 1 |
| 2026-11-02 | $-0.09 | $1,150,000 | 1 / 1 |
| 2026-11-03 | $-0.09 | $1,150,000 | 1 / 1 |
| 2026-11-04 | $-0.09 | $1,150,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.